UK’s biotech pulse is picking up again

The UK life sciences sector is slowly recovering with a mix of hard‑built resilience and cautious optimism. After a few bruising years of global financial contraction, the industry generally and early‑stage companies in particular are still navigating a tight capital environment. 

Yet the country’s innovation engine continues to fire at full strength, powered by world‑class science and global excellence in technology, biotech, AI, and the convergence of tech and life science, according to Jane Wall, Managing Director of the UK’s BioIndustry Association (BIA).

AstraZeneca’s Discovery Centre in Cambridge.

A tough environment

When Wall reflects on the landscape, she does so from the perspective of someone who has spent a decade at BIA, at the center of the ecosystem. She has seen the industry weather one of its most turbulent financial periods in recent memory.

“Globally it’s been pretty difficult and the UK has also suffered, like everybody else,” she says. “It’s been an incredibly tough environment for the sector, particularly for early stage companies.”

The BIA’s annual UK Biotech Financing 2025 report underscored that reality: total biotech equity financing fell sharply, venture capital contracted and was concentrated into a handful of large rounds, and not a single UK biotech completed an IPO for the third year in a row.

M&A was the sole bright spot last year, with global pharma continuing to view UK assets as strategically valuable.

Momentum is building

But the drab picture began to shift in a more positive direction at the end of last year, and the start of 2026 suggests that momentum is building. The BIA’s most recent report, covering the first quarter of this year, shows venture capital rising to £516 million, a 17% increase from the previous quarter, and deal count jumping 60% year‑on‑year. With cautious optimism, the report suggests that a sustained recovery could be taking hold.

Seed rounds and series A have been quite challenging. It’s linked to investors favoring slightly more mature deals, which are perhaps a little more de-risked.

Wall is nevertheless realistic about the unevenness beneath the surface. Early‑stage companies remain the most exposed.

“For the first time over the last couple of years, we’ve seen quite a slowdown in very early stage funding. Seed rounds and series A have been quite challenging. It’s linked to investors favoring slightly more mature deals, which are perhaps a little more de-risked,” she explains.

Liz Kendall, Secretary of State at the Department for Science, Innovation and Technology, speaking at a BIA gala dinner.

A great opportunity

This cooling at the earliest stages is unusual for the UK, according to Wall. The report shows that later‑stage Series B+ rounds accounted for the largest share of capital at the start of the year. For a sector built on long‑term innovation and dependent on a vibrant startup environment, the imbalance may have a ripple effect, especially if the trend continues.

It’s incredibly busy right now, which is great news because it means that there’s lots going on in the background with regards to deals and with regards to growth of companies.

And yet, Wall sees unmistakable signs of life returning to life sciences. Recruiters, investors, and dealmakers are all reporting heightened activity. Wall notes that, encouragingly, she sees more capital being deployed through funds as well.

“We have a great opportunity, and we know that there’s lots of movement in the sector now,” she says. “It’s incredibly busy right now, which is great news because it means that there’s lots going on in the background with regards to deals and with regards to growth of companies – a lot of things are starting to happen that I hope we will see come to fruition throughout the rest of the year.”

The Bridge Of Sighs in Cambridge.

The one factor no one can control is geopolitics.

“The elephant in the room is that we’re geopolitically in a very challenging situation. Who knows what the summer will bring in terms of energy crises and other things that could detract from the recovery,” Wall notes. “None of us have a crystal ball or indeed much power over the world situation, but we see a positive trajectory after an incredibly difficult time.”